IL-1-like cytokine antibodies
View Patent ↗Nucleic acids encoding mammalian, e.g., primate, IL-1ζ, purified IL-1ζ polypeptides and fragments thereof. Binding proteins, e.g., antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.
1. An isolated or purified binding compound comprising an antigen binding site of an antibody that specifically binds to a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2 at an epitope comprising at least one sequence selected from the group consisting of:
FVHTSR (amino acids 45-50, SEQ ID NO: 2);
KKFSIHD (amino acids 58-64, SEQ ID NO: 2);
VLVLDS (amino acids 69-74, SEQ ID NO: 2);
NLIAVP (amino acids 76-81, SEQ ID NO: 2); and
SRNMLES (amino acids 163-169, SEQ ID NO: 2).
2. The binding compound of claim 1 , wherein the binding site of the antibody specifically binds to a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2 at an epitope comprising at least one sequence selected from the group consisting of:
KKFSIHD (amino acids 58-64, SEQ ID NO: 2);
VLVLDS (amino acids 69-74, SEQ ID NO: 2); and
NLIAVP (amino acids 76-81, SEQ ID NO: 2).
3. The binding compound of claim 1 , wherein the binding compound is a humanized antibody.
4. The binding compound of claim 1 , wherein the binding compound is an Fv, Fab, or F(ab′) 2 fragment.
5. The binding compound of claim 1 , wherein the binding compound is glycosylated.
6. A binding composition comprising the binding compound of claim 1 , and a carrier, wherein the carrier is formulated for oral, rectal, nasal, topical, parenteral, subcutaneous, intramuscular, intravenous, or intradermal administration.
7. A kit comprising:
a) the binding compound of claim 1 ;
b) a compartment;
b) instructions for use; and
c) a polypeptide comprising the amino acid sequence of SEQ ID NO: 2.
8. A method of making the binding compound of claim 1 , comprising immunizing an animal with an immunogenic amount of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2, or an antigenic fragment thereof.
9. A method of producing an antigen:antibody complex, comprising contacting a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 with the antibody of claim 1 and allowing a complex to form.
10. An isolated or purified binding compound comprising an antigen binding site of an antibody that specifically binds to a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2 at an epitope comprising at least one sequence selected from the group consisting of:
SRKVKSLNPKKF (amino acids 49-60, SEQ ID NO: 2);
HDQDHKVLVLDS (amino acids 63-74, SEQ ID NO: 2);
NLIAVPDKNYIR (amino acids 76-87, SEQ ID NO: 2); and
FYRAQVGSRNML (amino acids 156-167, SEQ ID NO: 2).
11. The binding compound of claim 10 , wherein the binding site of the antibody specifically binds to a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2 at an epitope comprising at least one sequence selected from the group consisting of:
SRKVKSLNPKKF (amino acids 49-60, SEQ ID NO: 2);
HDQDHKVLVLDS (amino acids 63-74, SEQ ID NO: 2); and
NLIAVPDKNYIR (amino acids 76-87, SEQ ID NO: 2).
12. The binding compound of claim 10 , wherein the binding compound is a humanized antibody.
13. The binding compound of claim 10 , wherein the binding compound is an Fv, Fab, or F(ab′) 2 fragment.
14. The binding compound of claim 10 , wherein the binding compound is glycosylated.
15. A binding composition comprising the binding compound of claim 10 , and a carrier, wherein the carrier is formulated for oral, rectal, nasal, topical, parenteral, subcutaneous, intramuscular, intravenous, or intradermal administration.
16. A kit comprising:
a) the binding compound of claim 10 ;
b) a compartment;
b) instructions for use; and
c) a polypeptide comprising the amino acid sequence of SEQ ID NO: 2.
17. A method of making the binding compound of claim 10 , comprising immunizing an animal with an immunogenic amount of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2, or an antigenic fragment thereof.
18. A method of producing an antigen:antibody complex, comprising contacting a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 with the antibody of claim 10 and allowing a complex to form.
19. An isolated or purified binding compound comprising an antigen binding site of an antibody that specifically binds to a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2 at an epitope found within amino acids 49-89 of SEQ ID NO: 2.